Needham has upgraded Medtronic (MDT) to a “Buy” rating from “Hold,” setting a price target of $121. This upgrade reflects a positive outlook on the medical equipment giant. The article also mentions recent news surrounding Medtronic, including an antitrust lawsuit verdict and planned acquisition of CathWorks.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Needham Upgrades Medtronic to Buy From Hold, Sets $121 Price Target
Needham has upgraded Medtronic (MDT) to a “Buy” rating from “Hold,” setting a price target of $121. This upgrade reflects a positive outlook on the medical equipment giant. The article also mentions recent news surrounding Medtronic, including an antitrust lawsuit verdict and planned acquisition of CathWorks.